ES2560003T3 - Inhibidores de la serina proteasa de VHC derivados de prolina macrocíclica - Google Patents
Inhibidores de la serina proteasa de VHC derivados de prolina macrocíclica Download PDFInfo
- Publication number
- ES2560003T3 ES2560003T3 ES11827336.6T ES11827336T ES2560003T3 ES 2560003 T3 ES2560003 T3 ES 2560003T3 ES 11827336 T ES11827336 T ES 11827336T ES 2560003 T3 ES2560003 T3 ES 2560003T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- cycloalkenyl
- cycloalkyl
- alkenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/123—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Un compuesto de Fórmula VII:**Fórmula** donde cada uno de R1', R2', R3' y R4' es independientemente R6, o R1 y R2', R2' y R3' o R3' y R4' combinados junto con los átomos de carbono a los que están unidos forman un anillo aromático o heteroaromático o cíclico o heterocíclico; - se selecciona entre -cicloalquilo C3-C12, 10 -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12, -cicloalquenilo C3-C12 sustituido; -heterocicloalquilo C3-C12 y -heterocicloalquilo C3-C12 sustituido; o - es**Fórmula** donde cada uno de R7 y R8 es independientemente, alquilo C1-C8 o alquenilo C2-C8 y cada uno está sustituido de manera independiente y opcional con uno o más halo; cada R6 se selecciona independientemente entre: (i) hidrógeno; halógeno; -NO2; -CN; o N3; (ii) -M-R3, donde M es O, S o NH; (iii) NR4R5; (iv) -alquilo C1-C8, -alquenilo C2-C8 o -alquinilo C2-C8 conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido o -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12, -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12 o -cicloalquenilo C3-C12 sustituido; (v) arilo; arilo sustituido; heteroarilo; o heteroarilo sustituido; y (vi) heterocicloalquilo o heterocicloalquilo sustituido; R3 se selecciona independientemente entre alquilo C1-C8; -alquenilo C2-C8 o -alquinilo C2-C8, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N, -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido o -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12, -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12, -cicloalquenilo C3-C12 sustituido; heterocíclico; heterocíclico sustituido; arilo; arilo sustituido; heteroarilo; y heteroarilo sustituido; cada R4 y R5 se selecciona independientemente entre H y R3, o R4 y R5, combinados junto con el nitrógeno al que están unidos forman un anillo heterocíclico; cada uno de R y R' se selecciona independientemente entre el grupo que consiste en: (i) -alquilo C1-C8, -alquenilo C2-C8 o -alquinilo C2-C8, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido o -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12, -cicloalquilo C3-C12 sustituido; -alquilcicloalquilo C4-C12, -alquilcicloalquilo C4-C12 sustituido; -cicloalquenilo C3-C12, -cicloalquenilo C3-C12 sustituido; -alquilcicloalquenilo C4-C12 o -alquilcicloalquenilo C4-C12 sustituido; (ii) arilo; arilo sustituido; heteroarilo; o heteroarilo sustituido; (iii) heterocicloalquilo o heterocicloalquilo sustituido; y (iv) hidrógeno; o deuterio.
Description
(v) arilo; arilo sustituido; heteroarilo; o heteroarilo sustituido; y
- (vi)
- heterocicloalquilo o heterocicloalquilo sustituido; A está ausente, o es -(C=O)-, -S(O)2-, -C(=N-OR1)-o -C(=N-CN)-;
- Ⓑ
- se selecciona entre -cicloalquilo C3-C12, -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12, -cicloalquenilo C3-C12 sustituido; -heterocicloalquilo C3-C12, -heterocicloalquilo C3-C12 sustituido;
- o Ⓑ es
10 donde cada uno de R7 y R8 es independientemente alquilo C1-C8 o alquenilo C2-C8 y cada uno está sustituido de manera independiente y opcional con uno o más halo; cada uno de M1 y M2 se selecciona independientemente entre O y NR1; cada R1 se selecciona independientemente en cada caso entre el grupo que consiste en:
15
- (i)
- hidrógeno;
- (ii)
- arilo; arilo sustituido; heteroarilo; o heteroarilo sustituido;
(iii) heterocicloalquilo o heterocicloalquilo sustituido; y
(iv) -alquilo C1-C8, -alquenilo C2-C8, o -alquinilo C2-C8 conteniendo cada uno 0, 1, 2 o 3 heteroátomos
20 seleccionados de O, S o N; -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido, o -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12, -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12, o -cicloalquenilo C3-C12 sustituido;
cada uno de L1 y L2 se selecciona independiente entre -alquileno C1-C8, -alquenileno C2-C8, o -alquinileno C2-C8,
25 conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -alquileno C1-C8 sustituido, alquenileno C2-C8 sustituido, o -alquinileno C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N;
-cicloalquileno C3-C12 o -cicloalquileno C3-C12 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos 30 seleccionados de O, S o N; -cicloalquenileno C3-C12 o -cicloalquenileno C3-C12 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N;
W está ausente, -O-, -S-, -NH-, -N(Me)-, -C(O)NH-o -C(O)N(Me)-;
35 X' es N o -C(R2)-, donde R2 se selecciona entre el grupo que consiste en:
- (i)
- hidrógeno, halógeno, CN, CF3, NO2, OR3, SR3, -NHS(O)2-R3, -NH(SO2)NR4R5 NR4R5, CO2R3, COR3, CONR4R5, N(R1)COR3; arilo; arilo sustituido; heteroarilo; o heteroarilo sustituido;
- (ii)
- heterocicloalquilo o heterocicloalquilo sustituido; y
40 (iii) -alquilo C1-C8, -alquenilo C2-C8 o -alquinilo C2-C8, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido o -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12, -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12 o -cicloalquenilo C3-C12 sustituido;
45 cada R3 se selecciona independientemente entre -alquilo C1-C8, -alquenilo C2-C8 o -alquinilo C2-C8, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N, alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido, o -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12, -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12, -cicloalquenilo C3-C12 sustituido; heterocíclico; heterocíclico sustituido; arilo; arilo sustituido; heteroarilo; y heteroarilo sustituido;
50 cada R4 y R5 se selecciona independientemente entre H y R3, o R4 y R5, combinados junto con el nitrógeno al que están unidos forman un anillo heterocíclico; cada uno de R y R' se selecciona independientemente entre el grupo que consiste en:
(i) -alquilo C1-C8, -alquenilo C2-C8, o -alquinilo C2-C8 conteniendo cada uno 0, 1, 2 o 3 heteroátomos
55 seleccionados de O, S o N; -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido, o -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12, -cicloalquilo C3-C12 sustituido; -alquilcicloalquilo C4-C12, -alquilcicloalquilo C4-C12 sustituido; -cicloalquenilo C3-C12, -cicloalquenilo C3-C12 sustituido; -alquilcicloalquenilo C4-C12, o -alquilcicloalquenilo C4-C12 sustituido;
(ii) arilo; arilo sustituido; heteroarilo; o heteroarilo sustituido; 60 (iii) heterocicloalquilo o heterocicloalquilo sustituido; y
(iv) hidrógeno o deuterio;
7
cada uno de M1 y M2 se selecciona independientemente entre O y NR1; cada R1 se selecciona independientemente en cada caso entre el grupo que consiste en:
(i) hidrógeno; 5 (ii) arilo; arilo sustituido; heteroarilo; o heteroarilo sustituido;
(iii) heterocicloalquilo o heterocicloalquilo sustituido; y
(iv) -alquilo C1-C8, -alquenilo C2-C8, o -alquenilo C2-C8 conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido, o -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12, -cicloalquilo
10 C3-C12 sustituido; -cicloalquenilo C3-C12, o -cicloalquenilo C3-C12 sustituido;
cada R3 se selecciona independientemente entre alquilo C1-8, -alquenilo C2-C8, o -alquinilo C2-C8 conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N, -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido, o -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo
15 C3-C12, -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12, -cicloalquenilo C3-C12 sustituido; heterocíclico; heterocíclico sustituido; arilo; arilo sustituido; heteroarilo; y heteroarilo sustituido; cada R4 y R5 se selecciona independientemente entre H y R3, o R4 y R5, combinados junto con el nitrógeno al que están unidos forman un anillo heterocíclico; cada uno de R y R' se selecciona independientemente entre el grupo que consiste en:
20
(i) -alquilo C1-C8, -alquenilo C2-C8, o -alquenilo C2-C8 conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido, o -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12, -cicloalquilo C3-C12 sustituido; -alquilcicloalquilo C4-C12, -alquilcicloalquilo C4-C12 sustituido; -cicloalquenilo C3-C12,
25 -cicloalquenilo C3-C12 sustituido; -alquilcicloalquenilo C4-C12, o -alquilcicloalquenilo C4-C12 sustituido;
(ii) arilo; arilo sustituido; heteroarilo; o heteroarilo sustituido;
(iii) heterocicloalquilo o heterocicloalquilo sustituido; y
(iv) hidrógeno; o deuterio;
30 G se selecciona entre -OH, -NHS(O)2-R3, -NH(SO2)NR4R5, y NR4R5; y R" se selecciona entre hidrógeno, metilo, etilo, y alilo.
La presente invención también presenta compuestos de Fórmula VII o y sus sales o ésteres farmacéuticamente
aceptables:
donde R1, R2, cada uno de R3' y R4' es independientemente R6, o R1' y R2', R2' y R3', o R3' y R4' tomados junto con los átomos a los que están unidos, forman un anillo aromático, heteroaromático, cíclico o heterocíclico;
- Ⓑ
- se selecciona entre -cicloalquilo C3-C12, -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12, -cicloalquenilo C3-C12 sustituido; -heterocicloalquilo C3-C12, y -heterocicloalquilo C3-C12 sustituido;
- o Ⓑ es
donde cada uno de R7 y R8 es independientemente alquilo C1-C8 o alquenilo C2-C8 y cada uno está sustituido de manera independiente y opcional con uno o más halo; cada R6 se ha seleccionado independientemente entre:
(i) hidrógeno; halógeno; -NO2; -CN; o N3;
10
es hidrógeno, y el otro se selecciona entre halo, metilo opcionalmente sustituido con uno o más halo, u -O-metilo opcionalmente sustituido con uno o más halo. También preferentemente, R1' y R2', o R2' y R3', o R3' y R4', tomados junto con los átomos de carbono a los que están unidos, forman un carbociclo o heterociclo de 5 o 6 miembros (por ejemplo, fenilo), y el resto de R1', R2', R3' y R4' preferentemente son hidrógeno.
Preferentemente, R3 es
10 Preferentemente, R' es
- más preferentemente
- 15
- Preferentemente, R es
- 20
- más preferentemente
En una realización, la presente invención presenta compuestos de Fórmula VII o sales farmacéuticamente aceptables 25 de los mismos, donde Ⓑ es
R' es vinilo
o difluorometilo
R3 es
y R es
En otra realización, la presente invención presenta compuestos de Fórmula VII o sales farmacéuticamente aceptables de los mismos, donde Ⓑ es
12
donde
A está ausente, o se selecciona entre -(C=O)-, -S(O)2-, -C(=N-OR1)-y -C(=N-CN)-;
5 Ⓑ se selecciona entre -cicloalquilo C3-C12, -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12, -cicloalquenilo C3-C12 sustituido; -heterocicloalquilo C3-C12 y -heterocicloalquilo C3-C12 sustituido;
M1 y M2 se seleccionan entre O y NR1; donde R1 se selecciona en cada caso entre el grupo que consiste en:
10 (i) hidrógeno;
(ii) arilo; arilo sustituido; heteroarilo; heteroarilo sustituido;
(iii) heterocicloalquilo o heterocicloalquilo sustituido; y
(iv) -alquilo C1-C8, -alquenilo C2-C8, o -alquinilo C2-C8 conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados independientemente entre O, S y N; -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido, o
15 -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12, o -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12, o -cicloalquenilo C3-C12 sustituido;
L1 y L2 se seleccionan independiente entre -alquileno C1-C8, -alquenileno C2-C8, o -alquinileno C2-C8, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados independientemente entre O, S y N; -alquileno C1-C8 sustituido, 20 alquenileno C2-C8 sustituido, o -alquinileno C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados entre
O, S o N; -cicloalquileno C3-C12, o -cicloalquileno C3-C12 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquenileno C3-C12, o -cicloalquenileno C3-C12 sustituido, conteniendo cada uno 0, 25 1, 2 o 3 heteroátomos seleccionados de O, S o N;
W está ausente, o se selecciona entre -O-, -S-, -NH-, -N(Me)-, -C(O)NH-, y -C(O)N(Me)-;
X e Y, tomados junto con los átomos de carbono a los que están unidos, forman un resto cíclico seleccionado entre 30 arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterocíclico, y heterocíclico sustituido;
X' se selecciona entre N y -C(R2)-, donde R2 se selecciona entre el grupo que consiste en:
(i) hidrógeno, halógeno, CN, CF3, NO2, OR1, SR1, -NHS(O)2-R2, -NH(SO2)NR3R4, NR3R4, CO2R1, COR1, 35 CONR1R2, N(R1)COR2;
(ii) arilo; arilo sustituido; heteroarilo; heteroarilo sustituido;
(iii) heterocicloalquilo o heterocicloalquilo sustituido; y
(iv) -alquilo C1-C8, -alquenilo C2-C8 o -alquinilo C2-C8 conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados independientemente entre O, S y N; -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido o
40 -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12 o -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12, o -cicloalquenilo C3-C12 sustituido;
cada uno de R y R' se selecciona independientemente entre el grupo que consiste en:
45 (i) -alquilo C1-C8, -alquenilo C2-C8, o -alquinilo C2-C8 conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados independientemente entre O, S y N; -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido, o -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12, o -cicloalquilo C3-C12 sustituido; -alquilcicloalquilo C4-C12, o -alquilcicloalquilo C4-C12 sustituido; -cicloalquenilo C3-C12, o -cicloalquenilo C3-C12 sustituido; -alquilcicloalquenilo C4-C12, o
50 -alquilcicloalquenilo C4-C12 sustituido;
(ii) arilo; arilo sustituido; heteroarilo; heteroarilo sustituido;
(iii) heterocicloalquilo o heterocicloalquilo sustituido; y
(iv) hidrógeno; deuterio;
55 G se selecciona entre -OH, -NHS(O)2-R3, -NH(SO2)NR4R5 y NR4R5;
R3 se selecciona entre:
(i) arilo; arilo sustituido; heteroarilo; heteroarilo sustituido; 60 (ii) heterocicloalquilo; heterocicloalquilo sustituido; y
(iii) -alquilo C1-C8, -alquenilo C2-C8 o -alquinilo C2-C8 conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N, -alquilo C1-C8 sustituido, -alquenilo C2-C8 sustituido, o -alquinilo C2-C8 sustituido, conteniendo cada uno 0, 1, 2 o 3 heteroátomos seleccionados de O, S o N; -cicloalquilo C3-C12, o -cicloalquilo C3-C12 sustituido; -cicloalquenilo C3-C12, o -cicloalquenilo C3-C12 sustituido; heterocíclico; heterocíclico
65 sustituido;
15
17
20
22
Claims (1)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38505810P | 2010-09-21 | 2010-09-21 | |
US385058P | 2010-09-21 | ||
US201161499994P | 2011-06-22 | 2011-06-22 | |
US201161499994P | 2011-06-22 | ||
US201161504616P | 2011-07-05 | 2011-07-05 | |
US201161504616P | 2011-07-05 | ||
PCT/US2011/052304 WO2012040167A1 (en) | 2010-09-21 | 2011-09-20 | Macrocyclic proline derived hcv serine protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2560003T3 true ES2560003T3 (es) | 2016-02-17 |
Family
ID=45817947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11827336.6T Active ES2560003T3 (es) | 2010-09-21 | 2011-09-20 | Inhibidores de la serina proteasa de VHC derivados de prolina macrocíclica |
Country Status (42)
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8936781B2 (en) * | 2009-05-13 | 2015-01-20 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis C virus inhibitors |
WO2011049908A2 (en) * | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
HUE028384T2 (en) | 2010-09-21 | 2016-12-28 | Enanta Pharm Inc | HCV serine protease inhibitors derived from macrocyclic proline |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
PT2909205T (pt) | 2012-10-19 | 2017-02-06 | Bristol Myers Squibb Co | Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2- a)(1,4)diazaciclopentadecinilo substituídos com 9-metilo como inibidores da protease não estrutural 3 (ns3) para o tratamento de infeções por vírus da hepatite c |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
US10286029B2 (en) * | 2013-03-14 | 2019-05-14 | Abbvie Inc. | Method for treating HCV |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
TW202002979A (zh) * | 2013-03-14 | 2020-01-16 | 美商艾伯維有限公司 | 治療hcv的方法 |
EP2968301B1 (en) * | 2013-03-14 | 2017-04-19 | AbbVie Inc. | Combination of two antivirals for treating hepatitis c |
US20180042982A1 (en) * | 2013-03-14 | 2018-02-15 | Abbvie Inc. | Methods for Treating HCV |
US20200368229A9 (en) * | 2013-03-14 | 2020-11-26 | Abbvie Inc. | Methods for Treating HCV |
CA2902569A1 (en) | 2013-03-15 | 2014-09-18 | Gilead Sciences, Inc. | Inhibitors of hepatitis c virus |
US20150119400A1 (en) * | 2013-10-25 | 2015-04-30 | Abbvie, Inc. | Methods for treating hcv |
PT3087086T (pt) * | 2013-12-23 | 2019-02-06 | Gilead Pharmasset Llc | Formas cristalinas de um tripéptido inibidor de hcv ns3 macrocíclico |
CA2934537C (en) * | 2013-12-23 | 2022-08-16 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
MX2016012722A (es) * | 2014-04-02 | 2016-12-16 | Abbvie Inc | Metodos para tratar el virus de la hepatitis c. |
WO2015188045A1 (en) | 2014-06-06 | 2015-12-10 | Abbvie Inc. | Crystal forms |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
US9809576B1 (en) | 2014-07-18 | 2017-11-07 | Abbvie Inc. | Synthetic route to anti-viral agents |
US9809534B1 (en) | 2014-07-21 | 2017-11-07 | Abbvie Inc. | Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof |
US10059969B1 (en) | 2014-10-03 | 2018-08-28 | Abbvie Inc. | Process for the preparation of (S)-2-amino-non-8-enoic acid |
US10316338B1 (en) | 2015-01-30 | 2019-06-11 | Abb Vie Inc. | Enzymatic process for the preparation of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropanecarboxylic acid |
WO2016134058A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
RU2018102809A (ru) * | 2015-06-26 | 2019-07-29 | Эббви Инк. | Твердые фармацевтические композиции для лечения вируса гепатита с |
US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
CA2991417A1 (en) | 2015-07-08 | 2017-01-12 | Abbvie Inc. | Methods for treating hcv |
EA201890334A1 (ru) * | 2015-07-17 | 2018-06-29 | Эббви Инк. | Твердые фармацевтические композиции для лечения вируса гепатита с |
KR101726567B1 (ko) | 2016-07-08 | 2017-04-13 | 박공영 | 수직형 식물 재배장치 |
US10689675B2 (en) | 2017-02-01 | 2020-06-23 | Abbvie Inc. | Enzymatic processes for the preparation of (±)-2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid and (±)-2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid |
CA2994496A1 (en) | 2017-02-14 | 2018-08-14 | Abbvie Inc. | Methods for treating hcv |
CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
WO2019046569A1 (en) * | 2017-09-01 | 2019-03-07 | Abbvie Inc. | METHODS FOR THE TREATMENT OF HCV |
JP2020536909A (ja) | 2017-10-12 | 2020-12-17 | アッヴィ・インコーポレイテッド | Hcvを処置するための方法 |
CN107739319A (zh) * | 2017-10-31 | 2018-02-27 | 上海同昌生物医药科技有限公司 | 一种Glecaprevir合成中间体及其胺盐的制备方法 |
WO2019084740A1 (zh) * | 2017-10-31 | 2019-05-09 | 上海同昌生物医药科技有限公司 | 一种Glecaprevir合成中间体及其胺盐的制备方法 |
CN108329332A (zh) * | 2018-03-16 | 2018-07-27 | 安徽华昌高科药业有限公司 | 一种制备Glecaprevir的方法 |
US20210023012A1 (en) | 2019-04-08 | 2021-01-28 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
KR20200142394A (ko) | 2019-06-12 | 2020-12-22 | 엘지디스플레이 주식회사 | 폴더블 디스플레이와 그 구동 방법 |
WO2021137256A1 (en) | 2020-01-03 | 2021-07-08 | Mylan Laboratories Limited | Polymorphic forms of glecaprevir |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
CN114085458A (zh) * | 2021-12-08 | 2022-02-25 | 宁波塑之华塑化有限公司 | 一种高强度高韧性阻燃聚丙烯复合材料及其制备方法 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
AU757783B2 (en) | 1997-08-11 | 2003-03-06 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
EP1058686B1 (en) | 1998-02-25 | 2006-11-02 | Emory University | 2'-fluoronucleosides |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
ID30204A (id) | 1999-12-27 | 2001-11-15 | Japan Tobacco Inc | Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat |
EA200200778A1 (ru) | 2000-02-18 | 2003-06-26 | Шайре Байокем Инк. | СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С В ОРГАНИЗМЕ ХОЗЯИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ПРОТИВ ФЛАВИВИРУСА, СОЕДИНЕНИЕ ФОРМУЛЫ Ib - АКТИВНЫЙ АГЕНТ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С ИЛИ ФЛАВИВИРУСА (ВАРИАНТЫ) |
EP1268525B1 (en) | 2000-04-05 | 2008-12-31 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
BR0115447A (pt) | 2000-11-20 | 2005-10-18 | Bristol Myers Squibb Co | Inibidores de tripeptìdeo de hepatite c |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
US6841566B2 (en) | 2001-07-20 | 2005-01-11 | Boehringer Ingelheim, Ltd. | Viral polymerase inhibitors |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
EP1429759A4 (en) | 2001-09-26 | 2004-12-15 | Bristol Myers Squibb Co | COMPOUNDS FOR TREATING HEPATITIS C VIRUS |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
ATE481106T1 (de) | 2002-05-20 | 2010-10-15 | Bristol Myers Squibb Co | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer |
ATE503764T1 (de) | 2002-05-20 | 2011-04-15 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
AU2003301959A1 (en) | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
ES2304511T3 (es) | 2002-06-04 | 2008-10-16 | Schering Corporation | Compuestos de pirazolo(1,5-a)pirimidina como agentes antivirales. |
US20040138109A1 (en) | 2002-09-30 | 2004-07-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Potent inhibitor of HCV serine protease |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US20050159345A1 (en) | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
CN1771050A (zh) | 2003-02-07 | 2006-05-10 | 益安药业 | 丙型肝炎丝氨酸蛋白酶的大环抑制剂 |
DE602004029866D1 (de) | 2003-03-05 | 2010-12-16 | Boehringer Ingelheim Pharma | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
CA2516016C (en) | 2003-03-05 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
GB0307891D0 (en) | 2003-04-04 | 2003-05-14 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
WO2004094452A2 (en) | 2003-04-16 | 2004-11-04 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
JP4778893B2 (ja) | 2003-04-18 | 2011-09-21 | エナンタ ファーマシューティカルズ インコーポレイテッド | キノキサリニル大環状のc型肝炎セリンプロテアーゼ阻害剤 |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
CN1791599A (zh) | 2003-05-21 | 2006-06-21 | 贝林格尔.英格海姆国际有限公司 | 丙型肝炎抑制剂化合物 |
WO2004113365A2 (en) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
CN1829709A (zh) | 2003-08-01 | 2006-09-06 | 健亚生物科技公司 | 对抗黄病毒的双环咪唑衍生物 |
WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
CA2536182C (en) | 2003-09-22 | 2012-07-24 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
RS20060259A (en) | 2003-10-14 | 2008-08-07 | Intermune Inc., | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2005049622A1 (ja) | 2003-11-19 | 2005-06-02 | Japan Tobacco Inc. | 5-5員縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての用途 |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
MXPA06005683A (es) | 2003-11-20 | 2006-12-14 | Schering Corp | Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c. |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2358333T3 (es) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
EP1718608B1 (en) | 2004-02-20 | 2013-07-17 | Boehringer Ingelheim International GmbH | Viral polymerase inhibitors |
US7705146B2 (en) | 2004-06-28 | 2010-04-27 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor peptide analogs |
UY29017A1 (es) | 2004-07-16 | 2006-02-24 | Boehringer Ingelheim Int | Inhibidores de polimerasa viral |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
CA2573346C (en) | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
AU2006242475B2 (en) | 2005-05-02 | 2011-07-07 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
EP2305695A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
AU2006275605B2 (en) | 2005-08-01 | 2011-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic peptides as HCV NS3 protease inhibitors |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
UY30437A1 (es) | 2006-06-26 | 2008-01-31 | Enanta Pharm Inc | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c |
US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
US7582605B2 (en) | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
US8138164B2 (en) | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8309540B2 (en) | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
JP2010507656A (ja) | 2006-10-24 | 2010-03-11 | メルク エンド カムパニー インコーポレーテッド | Hcvns3プロテアーゼ阻害剤 |
KR101615500B1 (ko) | 2006-10-27 | 2016-04-27 | 머크 샤프 앤드 돔 코포레이션 | Hcv ns3 프로테아제 억제제 |
ES2444575T3 (es) | 2006-10-27 | 2014-02-25 | Merck Sharp & Dohme Corp. | Inhibidores de la proteasa NS3 del VHC |
US8377872B2 (en) | 2007-04-26 | 2013-02-19 | Enanta Pharmaceuticals, Inc. | Cyclic P3 tripeptide hepatitis C serine protease inhibitors |
WO2008134397A1 (en) | 2007-04-26 | 2008-11-06 | Enanta Pharmaceuticals, Inc. | Aza-tripeptide hepatitis c serine protease inhibitors |
US20080267917A1 (en) | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
WO2009010804A1 (en) | 2007-07-19 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
WO2009064955A1 (en) | 2007-11-14 | 2009-05-22 | Enanta Pharmaceuticals, Inc. | Macrocyclic tetrazolyl hepatitis c serine protease inhibitors |
JP5529036B2 (ja) | 2007-12-05 | 2014-06-25 | エナンタ ファーマシューティカルズ インコーポレイテッド | フッ素化トリペプチドhcvセリンプロテアーゼ阻害剤 |
MX2010006209A (es) | 2007-12-05 | 2010-08-10 | Enanta Pharm Inc | Derivados de quinoxalinilo. |
WO2009079353A1 (en) | 2007-12-14 | 2009-06-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic hcv serine protease inhibitors |
US8222203B2 (en) | 2007-12-14 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Macrocyclic oximyl hepatitis C serine protease inhibitors |
US8283309B2 (en) | 2007-12-20 | 2012-10-09 | Enanta Pharmaceuticals, Inc. | Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors |
JP5608563B2 (ja) | 2008-02-25 | 2014-10-15 | メルク・シャープ・アンド・ドーム・コーポレーション | 治療用化合物 |
CA2719008A1 (en) | 2008-03-20 | 2009-09-24 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors |
AU2009241445A1 (en) | 2008-04-28 | 2009-11-05 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US8211891B2 (en) * | 2008-04-30 | 2012-07-03 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors |
RS53420B (en) * | 2008-07-22 | 2014-12-31 | Msd Italia S.R.L. | MACROCYCLIC COMPOUNDS OF HINOXALINE, WHICH IS AN INHIBITOR OF HCV NS3 PROTEASES WITH OTHER HCV AGENTS |
US8936781B2 (en) | 2009-05-13 | 2015-01-20 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis C virus inhibitors |
WO2011014487A1 (en) | 2009-07-30 | 2011-02-03 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
WO2011049908A2 (en) | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
HUE028384T2 (en) | 2010-09-21 | 2016-12-28 | Enanta Pharm Inc | HCV serine protease inhibitors derived from macrocyclic proline |
WO2012040040A1 (en) | 2010-09-21 | 2012-03-29 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
-
2011
- 2011-09-20 HU HUE11827336A patent/HUE028384T2/en unknown
- 2011-09-20 DK DK11827336.6T patent/DK2618831T3/en active
- 2011-09-20 BR BR112013006693-8A patent/BR112013006693B1/pt active IP Right Grant
- 2011-09-20 PL PL11827336T patent/PL2618831T3/pl unknown
- 2011-09-20 MY MYPI2013700450A patent/MY164754A/en unknown
- 2011-09-20 EP EP15202935.1A patent/EP3020723A1/en not_active Withdrawn
- 2011-09-20 CR CR20180517A patent/CR20180517A/es unknown
- 2011-09-20 UY UY0001038339A patent/UY38339A/es not_active Application Discontinuation
- 2011-09-20 CN CN201510204986.9A patent/CN104829688B/zh active Active
- 2011-09-20 KR KR1020187024775A patent/KR101990279B1/ko active IP Right Grant
- 2011-09-20 UA UAA201305119A patent/UA116616C2/uk unknown
- 2011-09-20 ES ES11827336.6T patent/ES2560003T3/es active Active
- 2011-09-20 KR KR1020207028340A patent/KR20200117065A/ko not_active Application Discontinuation
- 2011-09-20 UY UY0001033617A patent/UY33617A/es active IP Right Grant
- 2011-09-20 KR KR1020137010100A patent/KR101894704B1/ko active IP Right Grant
- 2011-09-20 AR ARP110103420A patent/AR083052A1/es active IP Right Grant
- 2011-09-20 WO PCT/US2011/052304 patent/WO2012040167A1/en active Application Filing
- 2011-09-20 MX MX2013003230A patent/MX343275B/es active IP Right Grant
- 2011-09-20 EP EP11827336.6A patent/EP2618831B1/en active Active
- 2011-09-20 NZ NZ703416A patent/NZ703416A/en unknown
- 2011-09-20 JP JP2013529408A patent/JP5857053B2/ja active Active
- 2011-09-20 CN CN201180055762.6A patent/CN103209703B/zh active Active
- 2011-09-20 EA EA201390425A patent/EA023009B1/ru active Protection Beyond IP Right Term
- 2011-09-20 TW TW100133824A patent/TWI523658B/zh active
- 2011-09-20 US US13/237,120 patent/US8648037B2/en active Active
- 2011-09-20 SI SI201130775A patent/SI2618831T1/sl unknown
- 2011-09-20 NZ NZ608720A patent/NZ608720A/en unknown
- 2011-09-20 PT PT118273366T patent/PT2618831E/pt unknown
- 2011-09-20 CA CA2812261A patent/CA2812261C/en active Active
- 2011-09-20 PE PE2013000545A patent/PE20140015A1/es active IP Right Grant
- 2011-09-20 RS RS20160169A patent/RS54638B1/en unknown
- 2011-09-20 AU AU2011305695A patent/AU2011305695B2/en active Active
- 2011-09-20 SG SG2013020672A patent/SG188618A1/en unknown
- 2011-09-20 EA EA201500728A patent/EA029145B1/ru active Protection Beyond IP Right Term
- 2011-09-20 KR KR1020197027736A patent/KR102128232B1/ko active IP Right Grant
- 2011-09-20 MX MX2016014229A patent/MX369246B/es unknown
- 2011-09-20 KR KR1020197016764A patent/KR102163902B1/ko active IP Right Grant
-
2013
- 2013-03-21 GT GT201300077AA patent/GT201300077AA/es unknown
- 2013-03-21 GT GT201300077A patent/GT201300077A/es unknown
- 2013-03-21 MX MX2019013037A patent/MX2019013037A/es unknown
- 2013-03-21 IL IL225412A patent/IL225412A/en active IP Right Grant
- 2013-03-21 CL CL2013000791A patent/CL2013000791A1/es unknown
- 2013-03-21 CO CO13056413A patent/CO6700835A2/es unknown
- 2013-03-21 CR CR20130135A patent/CR20130135A/es unknown
- 2013-03-21 DO DO2013000062A patent/DOP2013000062A/es unknown
- 2013-03-27 ZA ZA2013/02317A patent/ZA201302317B/en unknown
- 2013-04-18 EC ECSP13012559 patent/ECSP13012559A/es unknown
- 2013-11-19 ZA ZA2013/08655A patent/ZA201308655B/en unknown
-
2014
- 2014-01-02 US US14/146,161 patent/US9220748B2/en active Active
- 2014-01-06 HK HK14100080.5A patent/HK1186979A1/zh unknown
- 2014-01-06 HK HK16112273.5A patent/HK1223955A1/zh unknown
- 2014-03-13 CL CL2014000612A patent/CL2014000612A1/es unknown
-
2015
- 2015-11-20 US US14/946,866 patent/US20160145298A1/en not_active Abandoned
- 2015-12-11 JP JP2015241811A patent/JP6352238B2/ja active Active
-
2016
- 2016-01-13 CY CY20161100029T patent/CY1117113T1/el unknown
- 2016-01-26 HR HRP20160083TT patent/HRP20160083T1/hr unknown
- 2016-04-11 SM SM201600100T patent/SMT201600100B/xx unknown
- 2016-06-29 AU AU2016204491A patent/AU2016204491A1/en not_active Abandoned
- 2016-10-06 US US15/287,042 patent/US20170088583A1/en not_active Abandoned
-
2017
- 2017-10-10 LU LU00037C patent/LUC00037I2/fr unknown
- 2017-10-24 CY CY2017033C patent/CY2017033I1/el unknown
- 2017-10-24 LT LTPA2017034C patent/LTC2618831I2/lt unknown
- 2017-10-26 HU HUS1700039C patent/HUS1700039I1/hu unknown
- 2017-10-27 NL NL300900C patent/NL300900I2/nl unknown
- 2017-11-10 NO NO2017056C patent/NO2017056I2/no unknown
- 2017-12-12 US US15/839,249 patent/US20180162905A1/en not_active Abandoned
-
2018
- 2018-06-05 JP JP2018107455A patent/JP6574023B2/ja active Active
- 2018-09-26 US US16/142,087 patent/US20190263860A1/en not_active Abandoned
-
2019
- 2019-08-13 JP JP2019148420A patent/JP2020015730A/ja active Pending
- 2019-08-21 DO DO2019000218A patent/DOP2019000218A/es unknown
- 2019-10-04 EC ECSENADI201972215A patent/ECSP19072215A/es unknown
- 2019-12-23 US US16/724,677 patent/US20200270303A1/en not_active Abandoned
-
2021
- 2021-01-15 JP JP2021004680A patent/JP2021063130A/ja not_active Ceased
- 2021-09-16 NO NO2021040C patent/NO2021040I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2560003T3 (es) | Inhibidores de la serina proteasa de VHC derivados de prolina macrocíclica | |
NO20064893L (no) | Syntese av boronsyre-estere og -syreforbindelser | |
BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
AR075090A1 (es) | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. | |
AR072162A1 (es) | Compuestos de ester boronato y composiciones farmaceuticas de los mismos | |
TW200745058A (en) | MMP-13 selective inhibitors | |
NI200900037A (es) | Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica. | |
TW200633704A (en) | N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library | |
AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
TNSN07397A1 (en) | Acetylene derivatives | |
NO20060664L (no) | N-substituerte benzimidazolyl C-kit inhibitorer | |
NO20082388L (no) | Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer | |
PE20090905A1 (es) | Compuestos heterociclicos de amidas como inhibidores de la proteincinasa | |
AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
ES2192520T3 (es) | Composicion farmaceutica. | |
AR087919A1 (es) | Heterociclos biciclicos como inhibidores de irak4 | |
ES2305452T3 (es) | Inhibidores de la catepsina cisteina y proteasa. | |
AR069464A1 (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
MY150289A (en) | Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof | |
CU24030B1 (es) | Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen | |
DOP2006000168A (es) | Dispositivos transdérmicos de liberación de fármaco que contienen drospirenona y métodos de liberación de los mismos | |
AR062258A1 (es) | Compuestos heterociclicos condensados de tieno-pirrol, composiciones farmaceuticas que los contienen y usos para el tratamiento de infecciones por hcv | |
NO20070173L (no) | Nye forbindelser | |
EA201070839A1 (ru) | Новые производные ацилцианопирролидинов |